Industry Briefing

A single destination for timely, editor-curated robotics news from around the world.

Misumi launches Misumi Americas as part of $1 billion global manufacturing investment

Misumi launches Misumi Americas as part of $1 billion global manufacturing investment

Japanese industrial components supplier Misumi Group has officially launched Misumi Americas, marking a significant step in its expansion strategy. The company has unveiled a $1 billion (¥150 billion) global investment program designed to enhance its digital manufacturing and supply chain capabilities. This initiative integrates Misumi’s existing industrial components business with an AI-powered manufacturing platform acquired from Fictiv, thereby broadening the company's operational scope. The investment aims to strengthen Misumi's position in the competitive manufacturing landscape by leveraging advanced technology to streamline processes and improve efficiency.

Components News additive manufacturing aerospace manufacturing ai manufacturing automation news
CEOs of NVIDIA and Lilly Share ‘Blueprint for What Is Possible’ in AI and Drug Discovery

CEOs of NVIDIA and Lilly Share ‘Blueprint for What Is Possible’ in AI and Drug Discovery

NVIDIA and Eli Lilly are collaborating to create a framework aimed at revolutionizing drug discovery, as announced during a recent fireside chat. NVIDIA's founder and CEO, Jensen Huang, discussed this initiative with Lilly's chair and CEO, Dave Ricks, highlighting the potential advancements in pharmaceutical research. The event took place on Monday, underscoring the companies' commitment to leveraging technology to enhance the efficiency and effectiveness of drug development. This partnership seeks to harness NVIDIA's expertise in artificial intelligence and computing power to accelerate the discovery process, ultimately aiming to bring innovative treatments to market more swiftly. By combining their resources and knowledge, both companies aspire to set a new standard in the industry, addressing the growing need for faster and more effective drug discovery methods.